Propagermanium: a nonspecific immune modulator for chronic hepatitis B.
Although antiviral agents have been adopted for the management of chronic hepatitis B, they have only limited efficacy because of the underlying impaired immune status. Propagermanium, a hydrophilic polymer of 3-oxygermyl propionate, has been reported to have potent immune modulatory activity associated with antiinflammatory and antineoplastic properties. For example, propagermanium augments lymphocyte functions in CD4 and CD8 cells, and in natural killer (NK) cells, and induces the production of several cytokines. A controlled pilot study of 16-week treatment with propagermanium for chronic hepatitis B (of moderate and mild grades on hepatic histology) revealed a sustained clearance of hepatitis B e (HBe) antigen and a favorable biochemical response at week 16 of treatment and at week 48 post-treatment. An open study also supported the clearance of hepatitis B virus from the blood and the possible improvement of histologic grading in the liver. There were few adverse events. A postmarketing survey, however, revealed the occurrence of moderate to severe liver damage after the treatment in about 4% of patients. Despite the exact nature of the liver damage being unclear, a putative cause is the swift removal of virus-infected hepatocytes by an immune reaction through the treatment. A subtle balance between host and viral conditions is the factor which most determines hepatitis B virus persistence. The rationale for a nonspecific immune modulator for the treatment of chronic hepatitis B will be the restoration of cellular immune responsiveness to viral infection. Although the cellular immunity for hepatitis B virus prior to the treatment should be studied, adequate observation of hepatic functions and viral markers in the recipients is clinically useful to predict liver failure during the treatment. In summary, the propagermanium regimen offers a potent and safe approach that is cost-effective for appropriate chronic hepatitis B patients with reserve hepatic capacity, and will provide new perspectives for immune therapy in chronic hepatitis B.
Hirayama
Chisato
C
Second Department of Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Suzuki
Hiroshi
H
Ito
Madoka
M
Okumura
Makoto
M
Oda
Toshitugu
T
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000410:Alanine Transaminase / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D005857:Germanium; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007369:Interferon Inducers / Q000009:adverse effects / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects / Q000473:pathology; D017114:Liver Failure, Acute / Q000139:chemically induced; D008297:Male; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects; D011358:Product Surveillance, Postmarketing; D011422:Propionates; D013997:Time Factors
D000276:Adjuvants, Immunologic; D006513:Hepatitis B e Antigens; D007369:Interferon Inducers; D009942:Organometallic Compounds; D011422:Propionates; D005857:Germanium; C066750:propagermanium; D000410:Alanine Transaminase